Rezolute, Inc. (RZLT)

3,8500 -0,1000 (-2,53%) Börsenschluss: 04:00PM EDT

Rezolute, Inc.

201 Redwood Shores Parkway
Suite 315
Redwood City, CA 94065
United States
650 206 4507
https://www.rezolutebio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 41

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Nevan Charles Elam J.D.	Founder, CEO & Acting Chairman of the Board	973,65k	N/A	1967
Dr. Brian Kenneth Roberts M.D.	Chief Medical Officer	738,86k	N/A	1975
Mr. Daron G. Evans M.B.A., M.S.	Chief Financial Officer	N/A	N/A	1974
Dr. Davelyn Eaves Hood M.B.A., M.D.	Director and Head of Scientific & Patient Affairs	N/A	N/A	N/A
Mr. Michael R. Deperro	Senior VP & Head of Corporate Development	N/A	N/A	N/A
Mr. Michael Covarrubias	Senior VP & Head of Program & Portfolio Management	N/A	N/A	N/A
Mr. Chris Milks	VP & Head of Finance	N/A	N/A	N/A
Dr. Raj Agrawal M.D.	VP & Head of Ophthalmological Clinical Development	N/A	N/A	N/A
Ms. Robyn Sweinhart	VP & Head of Quality	N/A	N/A	N/A
Ms. Erin O'Boyle	Senior VP & Head of Clinical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Corporate Governance

Rezolute, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.